(All fields required)
Please enter a valid email.
Please enter your name.
The Sickle Cell and Hemoglobin program is home to specialists with a wide variety of backgrounds and areas of focus. As a team, this diversity makes us better prepared to care for your child’s unique needs. Learn more about our faculty and staff.
Punam Malik, MD Director, Comprehensive Sickle Cell Program
Director, Comprehensive Sickle Cell Program
Program Leader, Molecular and Gene Therapy Program
Associate Professor, UC Department of Pediatrics
Arumugam P, Malik P. Genetic therapy for beta-thalassemia: from the bench to the bedside. Hematology Am Soc Hematol Educ Program. 2010;2010:445-50.
Perumbeti A, Malik P. Therapy for beta-globinopathies: a brief review and determinants for successful and safe correction. Ann N Y Acad Sci. 2010 Aug;1202:36-44. Review.
Perumbeti A, Malik P. Genetic correction of sickle cell anemia and beta-thalassemia: progress and new perspective. Scientific World Journal. 2010 Apr 13;10:644-54. Review.
Sundaram N, Tailor A, Mendelsohn L, Wansapura J, Wang X, Higashimoto T, Pauciulo MW, Gottliebson W, Kalra VK, Nichols WC, Kato GJ, Malik P. High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Blood. 2010 Jul 8;116(1):109-12.
Wang D, Zhang W, Kalfa TA, Grabowski G, Davies S, Malik P, Pan D. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19958-63.
Arumugam PI, Urbinati F, Velu CS, Higashimoto T, Grimes HL, Malik P. The 3' region of the chicken hypersensitive site-4 insulator has properties similar to its core and is required for full insulator activity. PLoS One. 2009 Sep 10;4(9):e6995.
Arumugam PI, Higashimoto T, Urbinati F, Modlich U, Nestheide S, Xia P, Fox C, Corsinotti A, Baum C, Malik P. Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region. Mol Ther. 2009 Nov;17(11):1929-37.
Perumbeti A, Higashimoto T, Urbinati F, Franco R, Meiselman HJ, Witte D, Malik P. A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. Blood. 2009 Aug 6;114(6):1174-85.
Urbinati F, Arumugam P, Higashimoto T, Perumbeti A, Mitts K, Xia P, Malik P. Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3'LTR. Mol Ther. 2009 Sep;17(9):1527-36.
Williams JP, Wu J, Johansson G, Rizvi TA, Miller SC, Geiger H, Malik P, Li W, Mukouyama YS, Cancelas JA, Ratner N. Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential. Cell Stem Cell. 2008 Dec 4;3(6):658-69.
Karen A. Kalinyak, MD Outpatient Clinical Director
Outpatient Clinical Director
Professor, UC Department of Pediatrics
Hematology; bone marrow failure; sickle cell anemia; hemoglobinopathy
Crosby LE, Barach I, McGrady ME, Kalinyak KA, Eastin AR, Mitchell MJ. Integrating interactive web-based technology to assess adherence and clinical outcomes in pediatric sickle cell disease. Anemia. 2012;2012:492428.
Debaun MR, Sarnaik SA, Rodeghier MJ, Minniti CP, Howard TH, Iyer RV, Inusa B, Telfer PT, Kirby-Allen M, Quinn CT, Bernaudin F, Airewele G, Woods GM, Panepinto JA, Fuh B, Kwiatkowski JK, King AA, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Sabio H, Gonzalez CE, Saccente SL, Kalinyak KA, Strouse JJ, Fixler JM, Gordon MO, Miller JP, Ichord RN, Casella JF. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, gender and relative high systolic blood pressure. Blood. 2012 Apr;119(16):3684-90.
McCarville MB, Rogers ZR, Sarnaik S, Scott P, Aygun B, Hilliard L, Lee MT, Kalinyak K, Owen W, Garro J, Schultz W, Yovetich N, Ware RE, SWiTCH Investigators. Effects of Chronic Transfusions on Abdominal Sonographic Abnormalities in Children with Sickle Cell Anemia. J Pediatr. 2012 Feb;160(2):281-285.
Kwiatkowski JL, Yim E, Miller S, Adams RJ, STOP 2 Study Investigators. Effect of transfusion therapy on transcranial Doppler ultrasonography velocities in children with sickle cell disease. Pediatr Blood Cancer. 2011 May;56(5):777-82.
George A, Benton J, Pratt J, Kim MO, Kalinyak KA, Kalfa TA, Joiner CH. The impact of the 2009 H1N1 influenza pandemic on pediatric patients with sickle cell disease. Pediatr Blood Cancer. 2011 Feb.
Wang W, Brugnara C, Snyder C, Wynn L, Rogers Z, Kalinyak K, Brown C, Qureshi A, Bigelow C, Neumayr L, Smith-Whitley K, Chui DH, Delahunty M, Woolson R, Steinberg M, Telen M, Kesler K. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. Br J Haematol. 2011 Jan;1365-2141.
Mizukawa B, George A, Pushkaran S, Weckbach L, Kalinyak K, Heubi JE, Kalfa TA. Cooperating G6PD mutations associated with severe neonatal hyperbilirubinemia and cholestasis. Pediatr Blood Cancer. 2011 May;56(5):840-2.
Dampier C, Lieff S, LeBeau P, Rhee S, McMurray M, Rogers Z, Smith-Whitley K, Wang W, Comprehensive Sickle Cell Centers Clinical Trial Consortium. Health-related quality of life in children with sickle cell disease: a report from the Comprehensive Sickle Cell Center Clinical Trial Consortium (CTC). Pediatr Blood Cancer. 2010 Sep;55(3):485-94.
Jordan LC, McKinstry RC 3rd, Kraut MA, Ball WS, Vendt BA, Casella JF, DeBaun MR, Strouse JJ, Silent Infarct Transfusion Trial Investigators. Incidental findings on brain magnetic resonance imaging of children with sickle cell disease. Pediatrics. 2010 Jul;126(1):53-61.
Vichinsky EP, Neumayr LD, Gold JI, Weiner MW, Rule RR, Truran D, Kasten J, Eggleston B, Kesler K, McMahon L, Orringer EP, Harrington T, Kalinyak K, DeCastro LM, Kutlar A, Rutherford C, Johnson C, Bessman JD, Jordan LB, Armstrong FD. Neuropsychological Dysfunction and Neuroimaging Adult Sickle Cell Anemia Study Group. JAMA. 2010;303(18):1823-31.
Theodosia A. Kalfa, MD, PhD
Assistant Professor, UC Department of Pediatrics
Signaling in erythrocytes; erythropoiesis; Sickle Cell disease; reactive oxygen species
Visit the Kalfa Lab.
George A, Pushkaran S, Konstantinidis DG, Koochaki S, Malik P, Mohandas N, Zheng Y, Joiner CH, Kalfa TA. Erythrocyte NADPH oxidase activity modulated by Rac GTPases, PKC, and plasma cytokines contributes to oxidative stress in sickle cell disease. Blood. Epub ahead of print. 2013.
Konstantinidis DG, Pushkaran S, Johnson JF, Cancelas JA, Manganaris S, Harris CE, Williams DA, Zheng Y, Kalfa TA. Signaling and cytoskeletal requirements in erythroblast enucleation. Blood. 2012 Jun 21;119(25):6118-27.
Hammill AM, Risinger MA, Joiner CH, Keddache M, Kalfa TA. Compound heterozygosity for two novel mutations in the erythrocyte protein 4.2 gene causing spherocytosis in a Caucasian patient. Br J Haematol. 2011 Jan 31.
Kalfa TA. Anchoring at an island to relieve stress. Blood. 2011 Jan 20;117(3):748-9.
Mizukawa B, George A, Pushkaran S, Weckbach L, Kalinyak K, Heubi JE, Kalfa TA. Cooperating G6PD mutations associated with severe neonatal hyperbilirubinemia and cholestasis. Pediatr Blood Cancer. 2010 Oct 14.
Konstantinidis DG, George A, Kalfa TA. Rac GTPases in erythroid biology. Transfus Clin Biol. 2010 Sep;17(3):126-30.
Kalfa TA, Pushkaran S, Zhang X, Johnson JF, Pan D, Daria D, Geiger H, Cancelas JA, Williams DA, Zheng Y. Rac1 and Rac2 GTPases are necessary for early erythropoietic expansion in the bone marrow but not in the spleen. Haematologica. 2010 Jan;95(1):27-35.
Mulloy JC, Cancelas JA, Filippi MD, Kalfa TA, Guo F, Zheng Y. Rho GTPases in hematopoiesis and hemopathies. Blood. 2010 Feb 4;115(5):936-47.
Daria D, Filippi MD, Knudsen ES, Faccio R, Li Z, Kalfa T, Geiger H. The retinoblastoma tumor suppressor is a critical intrinsic regulator for hematopoietic stem and progenitor cells under stress. Blood. 2008 Feb 15;111(4):1894-902.
Genetic Manipulation of Red Cell Volume Regulation. National Heart, Lung, and Blood Institute. Apr 2008 - Mar 2013. #U54 HL070871.
Rho GTPases in Terminal Erythroid Maturation. Principal Investigator. NIH/NHLBI. Sep 2012 - Jun 2016. #1R01HL116352.
TCD with Transfusions Changing to Hydroxyurea. Co-investigator. NIH/Baylor. Aug 2009 - Jul 2014. #R01HL095647.
Charles T. Quinn, MD, MS Director, Hematology Clinical and Translational Research
Director, Hematology Clinical and Translational Research
Sickle cell disease; thalassemia; hemoglobinopathies; anemia; autoimmune hemolytic anemia; disorders of red blood cells; iron overload and iron chelation; chronic transfusion therapy; immune thrombocytopenia (ITP); neutropenia; stroke
Epidemiology, pathophysiology, treatment and prevention of brain injury (structural and cognitive) in sickle cell disease; measurement of red blood cell turnover in sickle cell disease; identification and treatment of cardiomyopathy and nephropathy in sickle cell disease; treatment and prevention of pain (VOC) in sickle cell disease; MRI methods of iron quantitation; new agents for immune thrombocytopenia (ITP)
Dr. Quinn’s main interests and expertise are in patient-oriented and translational research in sickle cell disease and thalassemia. His formal clinical and translational research training has included: (1) the NIH-K30 Curriculum in Patient-Oriented Research; (2) the Clinical Research Training Institute of the American Society of Hematology; (3) the NIH-K12/KL2 Clinical Scholars Program; and (4) a Master’s degree in Clinical Sciences. Dr. Quinn is a member of the Editorial Board for Pediatric Blood and Cancer and the Board of Contributing Editors for The Hematologist. Dr. Quinn is on the Medical Advisory Board for the Cooley’s Anemia Foundation, and he is a member of the Committee on Educational Affairs of the American Society of Hematology. Locally, he is the medical director of the Ohio Department of Health Regional Sickle Cell Services Program – Region 1.
MD: University of Texas Southwestern Medical Center, Dallas, TX, 1994.
MS: University of Texas Southwestern Medical Center, Dallas, TX, 2008.
Residency & Chief Residency: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 1998.
Fellowship: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 2001.
Certifications: Pediatrics, 1998; Pediatric Hematology-Oncology, 2002.
McCavit TL, Xuan L, Zhang S, Flores G, Quinn CT. National trends in incidence rates of hospitalization for stroke in children with sickle sell disease. Pediatr Blood Cancer. Epub ahead of print. 2013.
Quinn CT, McKinstry RC, Dowling MM, Ball WS, Kraut MA, Casella JF, Dlamini N, Ichord RN, Jordan LC, Kirkham FJ, Noetzel MJ, Roach ES, Strouse JJ, Kwiatkowski JL, Hirtz D, DeBaun MR. Acute silent cerebral ischemic events in children with sickle cell anemia. JAMA Neurol (formerly Arch Neurol). 2013;70(1):58-65.
Dowling MM, Quinn CT, Plumb P, Rogers ZR, Rollins NK, Koral K, Buchanan GR. Acute silent cerebral ischemia and infarction during acute anemia in children with and without sickle cell disease. Blood. 2012;120(19):3891-7.
Trachtenberg FL, Mednick L, Kwiatkowski JL, Neufeld E, Haines D, Pakbaz Z, Thompson AA, Quinn CT, Grady R, Sobota A, Olivieri N, Horne R, Yamashita R; Thalassemia Clinical Research Network. Beliefs about chelation among thalassemia patients. Health Qual Life Outcomes. 2012;10:148(1-21).
Quinn CT, Dowling MM. Cerebral tissue hemoglobin saturation in children with sickle cell disease. Pediatr Blood Cancer. 2012;59(5):881-887.
Fung EB, Xu Y, Trachtenberg F, Odame I, Kwiatkowski JL, Neufeld EJ, Thompson AA, Boudreaux J, Quinn CT, Vichisnky EP. Inadequate dietary intake in patients with thalassemia. J Acad Nutr Diet. 2012;112(7):980-990.
DeBaun MR, Sarnaik SA, Rodeghier MJ, Minniti CP, Howard TH, Iyer RV, Inusa B, Telfer PT, Kirby-Allen M, Quinn CT, Bernaudin F, Airewele GE, Woods GM, Panepinto JA, Fuh B, Kwiatkowski JK, King AA, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Sabio H, Gonzalez CE, Saccente SL, Kalinyak KA, Strouse JJ, Fixler JM, Hirtz DG, Gordon MO, Miller JP, Ichord, RN, Casella JF. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, gender and relative high systolic blood pressure. Blood. 2012;119(16):3684-90.
Kwiatkowski JL, Kim H-Y, Thompson AA, Quinn CT, Mueller BU, Odame I, Giardina PJ, Vichisnky EP, Boudreaux JM, Porter JB, Coates T, Olivieri NF, Neufeld EJ, Thalassemia Clinical Research Network. Chelation Use and Iron Burden in North American and British Thalassemia Patients: A report from the Thalassemia Longitudinal Cohort. Blood. 2012;119(12):2746-53.
McCavit TL, Lin H, Zhang S, Ahn C, Flores G, Quinn CT. Hospitalization for invasive pneumococcal disease in a national sample of children with sickle cell disease before and after PCV7 licensure. Pediatr Blood Cancer. 2012;58(6):945-9.
Quinn CT, Stuart MJ, Kesler K, Ataga KI, Wang WC, Styles L, Smith-Whitley K, Wun T, Raj A, Hsu L, Krishnan S, Kuypers FA, Setty S, Rhee S, Key NS, Buchanan GR. Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. Br J Haematol. 2011;155(2):263-7.
Measuring RBC Turnover by Stable Isotope Labeling in SCD. Principle Investigator. CCTST T1 Pilot Grant (CTSA). Jun 2012 - May 2013.
Hydroxyurea to prevent CNS complications of sickle cell disease in children. Co-Investigator. National Institutes of Health (NHLBI). Sep 2011 - Jul 2013. # R34HL108756.
A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia. Co-Investigator. National Institutes of Health (NHLBI). Apr 2012 - Mar 2017. #P50HL110790.
Lori E. Crosby, PsyD
Adolescents; sickle cell disease; transition; chronic pain; migraines; cultural competence
Community-based research; self-management; quality improvement; sickle cell disease; health disparities
Visit the Crosby Lab.
PsyD: Wright State University, Dayton, Ohio, 1995.
Residency: Cincinnati Children's Hospital Medical Center.
Fellowship: Clinical Psychology, INTERACT Behavioral Healthcare Services Inc, Columbus, OH, 1995-1996.
Hines J, Mitchell M, Crosby L, Johnson A, Valenzuela J, Kalinyak K, Joiner C. Engaging Patients with Sickle Cell Disease and their Families in Disease Education, Research, and Community Awareness. J Prevent Intervent Comm. 2011.
Neal-Barnett A, Stadulis M, Payne MR, Crosby L, Mitchell M, Williams L, Costa CW. In the company of my sisters: Sister circles as an anxiety intervention for professional African American women. J Affect Disord. 2011 Mar;129(1-3):213-8.Oliver-Carpenter G, Barach I, Crosby LE, Valenzuela J, Mitchell MJ. Disease management, coping, and functional disability in pediatric sickle cell disease. J Natl Med Assoc. 2011 Feb;103(2):131-7.
Lynch-Jordan AM, Kashikar-Zuck S, Crosby LE, Lopez WL, Smolyansky BH, Parkins IS, Luzader CP, Hartman A, Guilfoyle SM, Powers SW. Applying quality improvement methods to implement a measurement system for chronic pain-related disability. J Pediatr Psychol. 2010 Jan-Feb;35(1):32-41. Brinkman WB, Sherman SN, Zmitrovich AR, Visscher MO, Crosby LE, Phelan KJ, Donovan EF. Parental angst making and revisiting decisions about treatment of attention-deficit/hyperactivity disorder. Pediatrics. 2009 Aug;124(2):580-9. Crosby LE, Modi AC, Lemanek KL, Guilfoyle SM, Kalinyak KA, Mitchell MJ. Perceived barriers to clinic appointments for adolescents with sickle cell disease. J Pediatr Hematol Oncol. 2009 Aug;31(8):571-6.
Bolling C, Crosby L, Boles R, Stark L. How pediatricians can improve diet and activity for overweight preschoolers: a qualitative study of parental attitudes. Acad Pediatr. 2009 May-Jun;9(3):172-8. Modi A, Crosby L, Guilfoyle S, Lemanek K, Witherspoon D, Mitchell M. Barriers to Treatment Adherence for Pediatric Patients with Sickle Cell Disease and their Families. Children’s Health Care. 2009.
Beidel D, Turner S, Sallee R, Ammerman R, Crosby L, Pathak S. SET-C vs. fluoxetine in the Treatment of Childhood Social Phobia. J Am Acad Child Adolesc Psych. 2007;46:1622-1632.
Mitchell MJ, Lemanek K, Palermo TM, Crosby LE, Nichols A, Powers SW. Parent perspectives on pain management, coping, and family functioning in pediatric sickle cell disease. Clin Pediatr (Phila). 2007 May;46(4):311-9.
Cincinnati Sickle Cell Newborn Screening Network. Co-Investigator. US Department of Health and Human Services. July 2008 - May 2011.
Improving Adherence to HU Therapy. Project Co-Investigator. Comprehensive Sickle Cell Center. April 2008 - March 2012.
Cincinnati Children's Place Outcomes Award. Principal Investigator. Cincinnati Children’s Hospital Medical Center. July 2011 - June 2013.Ohio Valley Sickle Cell Network. Co-Investigator. US Department of Health and Human Services. September 2010 - August 2014.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2013 Cincinnati Children's Hospital Medical Center